12:00 AM
 | 
May 18, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Darusentan: Phase III data

Data from the double-blind, international Phase III DAR-311 trial in 379 patients showed that 50, 100 and 300 mg darusentan met secondary endpoints of a significant reduction from baseline in mean 24-hour ambulatory SBP and DBP vs. placebo (p<0.001 for each group) and a...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >